Israel Cancer Research Fund ICRF

Israel Cancer Research Fund ICRF Israel Cancer Research Fund is the largest non-governmental funder of cancer research in Israel.

Today, on National Cancer Survivors Day, we honor the millions of survivors whose lives have been changed by advances in...
06/07/2026

Today, on National Cancer Survivors Day, we honor the millions of survivors whose lives have been changed by advances in cancer research.

Many of today’s treatments—from immunotherapy to targeted therapies and precision medicine—were made possible through decades of scientific discovery. Through the support of our generous community, ICRF-funded scientists continue advancing the breakthroughs that help patients live longer, healthier lives.

We honor survivors, remember those we have lost, and remain committed to a future where more lives are saved through cancer research.

It was inspiring to see a strong Israeli delegation, including several ICRF-funded scientists, at this week’s American S...
06/03/2026

It was inspiring to see a strong Israeli delegation, including several ICRF-funded scientists, at this week’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. ASCO brings together more than 44,000 of the world’s leading oncology professionals to learn, collaborate, and advance the future of cancer care.

Several ICRF-funded researchers presented their work at this year’s meeting, including Prof. Irit Ben-Aharon MD, PhD., Director of the Fishman Oncology Center at Rambam Health Care Campus, who shared her important research on long-term child outcomes following cancer during pregnancy.

While in Chicago to present at ASCO, ICRF-funded researcher Dr. Yaacov Richard Lawrence of Sheba Medical Center, recipient of the ICRF Rolfe Pancreatic Cancer Foundation Collaborative Project Grant for Pancreatic Cancer, also met with ICRF supporters. In a conversation with ICRF Executive Director Alan Herman, he discussed how his precision radiotherapy research is bringing new hope to patients facing pancreatic cancer.

We are proud to support groundbreaking research that advances cancer treatment and care while ensuring that Israeli science remains at the forefront of the global fight against cancer.

Photo credit for Prof. Irit Ben-Aharon: Fishman Oncology Center

With warmer months bringing more time outdoors, awareness of skin cancer and melanoma becomes especially important. 1 in...
05/27/2026

With warmer months bringing more time outdoors, awareness of skin cancer and melanoma becomes especially important.

1 in 5 Americans will develop skin cancer by age 70, making it the most common cancer in the United States.

May is Skin Cancer and Melanoma Awareness Month, and ICRF is proud to support research related to these cancers that deepens understanding of disease development, improves early detection, and advances more effective treatment options.

Run historic streets. Fuel lifesaving research. Join at Philadelphia Marathon Weekend on November 21, 2026! 🏃‍♂️💙Wheth...
05/20/2026

Run historic streets. Fuel lifesaving research. Join at Philadelphia Marathon Weekend on November 21, 2026! 🏃‍♂️💙

Whether you run the 8K, half marathon, or full marathon, you’ll experience one of the country’s most historic and scenic race weekends while helping accelerate Israel's groundbreaking cancer discoveries.

Run with purpose. Run with .

Learn more and sign up: https://www.icrfonline.org/events/philadelphia-marathon-weekend-2026/

Did you know that bladder cancer has one of the highest recurrence rates of any cancer? Nearly 70% of cases return after...
05/19/2026

Did you know that bladder cancer has one of the highest recurrence rates of any cancer? Nearly 70% of cases return after treatment, which underscores the critical need for better therapies. Research also shows that while smoking is widely linked to lung cancer, it is the single largest risk factor for bladder cancer as well.

This May, Bladder Cancer Awareness Month, we are proud to highlight an immunotherapy research advancement for bladder cancer by Professors Gilad Bachrach and Ofer Mandelboim at The Hebrew University of Jerusalem. Funded in part by ICRF and recently published in the journal Cells, the study shows that an inactivated strain of E. coli bacteria triggered a strong immune response against bladder tumors with lower toxicity than standard treatment. By pioneering safer, more effective solutions, this innovative research offers new hope for bladder cancer patients worldwide.

This May, Brain Cancer Awareness Month, we recognize the urgent need for more research into this disease, and ICRF-funde...
05/14/2026

This May, Brain Cancer Awareness Month, we recognize the urgent need for more research into this disease, and ICRF-funded scientists are leading the way toward discoveries that bring hope to patients and families worldwide.

Brain tumors account for about 1% of all new cancer cases in the U.S. each year, yet they remain among the most difficult cancers to treat. For glioblastoma, the most common and most severe form, the five-year survival rate is approximately 7%.

ICRF grantee Prof. Tali Ilovitsh at Tel Aviv University - Global TAU is developing a noninvasive method to better detect and understand glioblastoma, with the goal of reducing the need for risky procedures and opening the door to more targeted, effective treatments.

Meet Prof. Ilovitsh and learn about her work here: https://www.youtube.com/watch?v=BXNEMyqcodY

Happy Mother’s Day! We honor and remember the women who mean the world to us, both those who are here with us and those ...
05/10/2026

Happy Mother’s Day!

We honor and remember the women who mean the world to us, both those who are here with us and those we carry in our hearts forever.

They inspire us to continue pressing forward in the fight against cancer, enabling Israel’s leading scientists to advance cancer research and bring hope to families everywhere.

On World Ovarian Cancer Day, we’re proud to highlight a newly published study in the journal Molecular Oncology from the...
05/08/2026

On World Ovarian Cancer Day, we’re proud to highlight a newly published study in the journal Molecular Oncology from the lab of ICRF-funded researcher Dr. Ruth Perets at Rambam Health Care Campus - Hospital. The team has identified key genes involved in the spread of high-grade serous ovarian cancer, the most common and aggressive form of the disease.

This discovery deepens scientific understanding of ovarian cancer biology and could help pave the way for new targeted therapies. It also reflects ICRF’s leadership in driving Israel’s innovative cancer research to improve outcomes and bring hope to patients worldwide.

This research was funded in part by the ICRF Beverley Librach Abshez Initiative for Ovarian and Female Reproductive System Cancers Grant and the ICRF Len and Susan Mark Phase II initiative for Ovarian and Uterine/MMMT Grant.

See the study here: https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.70235

Address

52 Vanderbilt Avenue Suite 1410
New York, NY
10017

Telephone

+12129699800

Website

Alerts

Be the first to know and let us send you an email when Israel Cancer Research Fund ICRF posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to Israel Cancer Research Fund ICRF:

Shortcuts

Featured

Share

Category